-

AI Stock Investigation: Robbins LLP Investigates C3.ai, Inc. (AI) on Behalf of Shareholders

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating C3.ai, Inc. (NYSE: AI) and its officers and directors to determine if they breached their fiduciary duties and violated securities laws in connection with the Company's initial public offering ("IPO"). C3.ai operates as an enterprise artificial intelligence ("AI") software company.

If you would like more information about our investigation of C3.ai, Inc., click here.

What Is This Case About: C3.ai went public on December 9, 2020, offering shares at $42.00 per share. Defendants - in the Offering Documents in support of the Company's IPO and during the class period - touted the Company's relationships with technology leaders, including Baker Hughes, and its "large and rapidly growing [total addressable] market," among other things.

However, these statements were false and misleading. Specifically, defendants and the Offering Documents failed to disclose that: (i) C3.ai's partnership with Baker Hughes was deteriorating and that the Company employed a flawed accounting methodology to conceal the deterioration of the partnership, (ii) C3.ai faced challenges in product adoption and significant salesforce turnover; and (iii) C3.ai overstated, inter alia, the extent of its investment in technology, description of its customers, its total addressable market, the pace of its growth, and the scale of alliances with its major business partners.

On February 22, 2022, Spruce Point Capital Management issued a report alleging it had uncovered "[e]vidence of a severely challenged partnership with Baker Hughes, a related party and C3.ai's largest customer" and "[s]igns of problematic financial reporting and accounting regarding the Baker Hughes joint venture and a revolving door in C3.ai's Chief Financial Officer position." The report further detailed, "[c]hallenges in product adoption and significant salesforce turnover make it unlikely that C3.ai will meet aggressive analyst estimates," as well as "[w]orrisome corporate governance practices and insider enrichment." On this news, C3.ai's stock price fell $1.01 per share, or almost 4%, on February 16, 2022. The stock trades significantly below the offering price of $42.00 per share.

Next Steps: If you acquired shares of C3.ai, Inc. (AI) pursuant to the Company's IPO or between December 9, 2020 and February 15, 2022, you have legal options. Contact us for more information.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:

Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form

About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against C3.ai, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

Robbins LLP

NYSE:AI

Release Summary
AI Stock Investigation: Robbins LLP Investigates C3.ai, Inc. (AI) on Behalf of Shareholders
Release Versions
$Cashtags

Contacts

Aaron Dumas
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
adumas@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Nektar Therapeutics Class Action Reminder – Robbins LLP Encourages NKTR Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders. The Company’s lead product candidate is rezpegaldesleukin, a novel, first-in-class regulat...

Robbins LLP Encourages SMCI Stockholders to Contact the Firm for Information About the Class Action Against Super Micro Computer, Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Super Micro Computer, Inc. (NASDAQ: SMCI) securities between April 30, 2024 and March 19, 2026. Super Micro is a technology company that designs, develops, and manufactures high-performance server and storage systems, primarily for artificial intelligence (“AI”), data center, and cloud solutions customers.For more information, submit a form, em...

Robbins LLP Urges COTY Stockholders to Contact the Firm for Information About the Class Action Against Coty Inc.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Coty Inc. (NYSE: COTY) common stock between November 5, 2025 and February 4, 2026. Coty together with its subsidiaries, manufactures, markets, distributes, and sells branded beauty products worldwide. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. What is the class period? November 5,...
Back to Newsroom